Financial Contrast: Mereo BioPharma Group (MREO) & The Competition

Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Mereo BioPharma Group to related companies based on the strength of its dividends, earnings, profitability, risk, analyst recommendations, institutional ownership and valuation.

Insider and Institutional Ownership

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Mereo BioPharma Group and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mereo BioPharma Group 2 3 3 0 2.12
Mereo BioPharma Group Competitors 9959 15361 45766 1602 2.54

Mereo BioPharma Group presently has a consensus target price of $1.67, indicating a potential upside of 541.03%. As a group, “Biotechnology” companies have a potential upside of 114.69%. Given Mereo BioPharma Group’s higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than its peers.

Profitability

This table compares Mereo BioPharma Group and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mereo BioPharma Group N/A -84.62% -71.44%
Mereo BioPharma Group Competitors -12,519.20% -215.47% -31.42%

Risk and Volatility

Mereo BioPharma Group has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Mereo BioPharma Group’s peers have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.

Earnings and Valuation

This table compares Mereo BioPharma Group and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Mereo BioPharma Group $500,000.00 -$41.88 million -6.50
Mereo BioPharma Group Competitors $750.67 million $10.42 million -17.98

Mereo BioPharma Group’s peers have higher revenue and earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Mereo BioPharma Group peers beat Mereo BioPharma Group on 7 of the 13 factors compared.

About Mereo BioPharma Group

(Get Free Report)

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and cancer. Established in 2015 and based in the United Kingdom, the company advances drug candidates that it has acquired or licensed from other pharmaceutical developers. Its rare-disease programs include setrusumab, an investigational antibody being developed for osteogenesis imperfecta, and alvelestat, an investigational oral drug being studied for lung disease associated with alpha-1 antitrypsin deficiency.

Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.